Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab With or Without Ipilimumab in Advanced Melanoma
NCT02736123Phase 2Withdrawn
- Sponsor
- University of Pittsburgh
- Start
- Oct 2016
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by University of Pittsburgh. Planned start Oct 2016; status: withdrawn.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02736123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736123.